Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.628690/full |
| _version_ | 1818959204297211904 |
|---|---|
| author | Chao Dong Jiao Wu Yin Chen Jianyun Nie Ceshi Chen Ceshi Chen |
| author_facet | Chao Dong Jiao Wu Yin Chen Jianyun Nie Ceshi Chen Ceshi Chen |
| author_sort | Chao Dong |
| collection | DOAJ |
| description | Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer. |
| first_indexed | 2024-12-20T11:37:55Z |
| format | Article |
| id | doaj.art-6baa08c2acad4f48b521ea0924c6e66e |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-20T11:37:55Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-6baa08c2acad4f48b521ea0924c6e66e2022-12-21T19:42:02ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-03-011210.3389/fphar.2021.628690628690Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast CancerChao Dong0Jiao Wu1Yin Chen2Jianyun Nie3Ceshi Chen4Ceshi Chen5Department of the Second Medical Oncology, The 3rd Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Kunming, ChinaDepartment of the Second Medical Oncology, The 3rd Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Kunming, ChinaDepartment of Urology, Changhai Hospital, Navy Medical University, Shanghai, ChinaDepartment of the Third Breast Surgery, The 3rd Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Kunming, ChinaKey Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, ChinaKIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, ChinaAlthough chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.https://www.frontiersin.org/articles/10.3389/fphar.2021.628690/fullchemotherapytargeted therapyendocrine therapydrug resistancePI3K |
| spellingShingle | Chao Dong Jiao Wu Yin Chen Jianyun Nie Ceshi Chen Ceshi Chen Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer Frontiers in Pharmacology chemotherapy targeted therapy endocrine therapy drug resistance PI3K |
| title | Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer |
| title_full | Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer |
| title_fullStr | Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer |
| title_full_unstemmed | Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer |
| title_short | Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer |
| title_sort | activation of pi3k akt mtor pathway causes drug resistance in breast cancer |
| topic | chemotherapy targeted therapy endocrine therapy drug resistance PI3K |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.628690/full |
| work_keys_str_mv | AT chaodong activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer AT jiaowu activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer AT yinchen activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer AT jianyunnie activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer AT ceshichen activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer AT ceshichen activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer |